{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:45:40Z","timestamp":1753868740274,"version":"3.41.2"},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Protocols"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This article describes a simple, reliable, efficient, and improved solution\u2010phase method for the gram\u2010scale chemical synthesis of RNA dinucleotides such as pA<jats:sub>m<\/jats:sub>pA, pA<jats:sub>m<\/jats:sub>pG, and pA<jats:sub>m<\/jats:sub>pU that utilizes phosphoramidite chemistry. The overall synthetic strategy involves three steps. The first step involves the coupling reaction between 5\u2032\u2010<jats:italic>O<\/jats:italic>\u2010MMT protected nucleoside\u20103\u2032\u2010<jats:italic>O<\/jats:italic>\u2010phosphoramidite and a protected nucleoside containing a free 5\u2032\u2010OH group in the presence of tetrazole, followed by the oxidation of phosphite triester using <jats:italic>tert<\/jats:italic>\u2010butyl hydroperoxide to give the corresponding protected N<jats:sub>m<\/jats:sub>pN. Next, the 5\u2032\u2010<jats:italic>O<\/jats:italic>\u2010MMT is cleaved under 3% trichloroacetic acid in dichloromethane conditions. Finally, the 5\u2032\u2010hydroxyl group is phosphorylated by the use of an activated bis(2\u2010cyanoethyl)\u2010<jats:italic>N<\/jats:italic>,<jats:italic>N<\/jats:italic>\u2010diisopropyl phosphoramidite using tetrazole, followed by the oxidation of trivalent to pentavalent phosphorus using <jats:italic>tert<\/jats:italic>\u2010butyl hydroperoxide and subsequent deprotection using ammonium hydroxide to afford the corresponding RNA dinucleotide, pN<jats:sub>m<\/jats:sub>pN, in good yields with high purity (&gt;99.5%). \u00a9 2022 Wiley Periodicals LLC.<\/jats:p>","DOI":"10.1002\/cpz1.583","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T13:45:15Z","timestamp":1667828715000},"source":"Crossref","is-referenced-by-count":0,"title":["Solution\u2010Phase Chemical Synthesis of Modified RNA Dinucleotides"],"prefix":"10.1002","volume":"2","author":[{"given":"Annamalai","family":"Senthilvelan","sequence":"first","affiliation":[{"name":"Life Sciences Solutions Group Thermo Fisher Scientific  Austin Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthian","family":"Shanmugasundaram","sequence":"additional","affiliation":[{"name":"Life Sciences Solutions Group Thermo Fisher Scientific  Austin Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anilkumar R.","family":"Kore","sequence":"additional","affiliation":[{"name":"Life Sciences Solutions Group Thermo Fisher Scientific  Austin Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"233","article-title":"Manufacturing of oligonucleotides","volume":"6","author":"Aduda P. V.","year":"2017","journal-title":"Comprehensive Medicinal Chemistry III"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/21.5.1213"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09489"},{"key":"e_1_2_5_5_1","doi-asserted-by":"crossref","unstructured":"Editorial [No Authors Listed]:Messengers of hope. [Editorial]. (2021).Nature Biotechnology 39 1. doi:10.1038\/s41587\u2010020\u201000807\u20101","DOI":"10.1038\/s41587-020-00807-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065\u20103527(00)55003\u20109"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0nj00041h"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.01.019"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21260"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.8b03386"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpnc.82"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4278"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.1c01037"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.2c00218"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/tcr.202200005"},{"key":"e_1_2_5_16_1","first-page":"26","article-title":"Current state of oligonucleotide therapeutics","volume":"40","author":"Shi X.","year":"2020","journal-title":"Pharmaceutical Engineering"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa032"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.1c01756"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN\u2010100002081"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.96"}],"container-title":["Current Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpz1.583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpz1.583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpz1.583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:27:36Z","timestamp":1692437256000},"score":1,"resource":{"primary":{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/10.1002\/cpz1.583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/cpz1.583"],"URL":"https:\/\/doi.org\/10.1002\/cpz1.583","archive":["Portico"],"relation":{},"ISSN":["2691-1299","2691-1299"],"issn-type":[{"type":"print","value":"2691-1299"},{"type":"electronic","value":"2691-1299"}],"subject":[],"published":{"date-parts":[[2022,11]]},"article-number":"e583"}}